title: Toward optimal therapy for inhibitors in hemophilia.
abstract: Treatment of patients with hemophilia A and B has undergone significant advances during the past 2 decades. However, despite these advances, the development of antibodies that inhibit the function of infused clotting factor remains a major challenge and is considered the most significant complication of hemophilia treatment. This chapter reviews current tools available for the care of patients with inhibitors and highlights areas where progress is imminent or strongly needed. For management of bleeding, bypassing agents remain the mainstay of therapy. Recombinant factor VIIa and activated prothrombin complex concentrates are similarly effective in populations of patients with hemophilia and inhibitors; however, individuals may show a better response to one agent over another. Recent studies have shown that prophylaxis with bypassing agents can reduce bleeding episodes by ∼50%-80%. The prophylactic use of bypassing agents is an important tool to reduce morbidity in patients before they undergo immune tolerance induction (ITI) and in those with persistent high titer inhibitors, but cost and lack of convenience remain barriers. Because of the significant burden that inhibitors add to the individual patient and the health care system, inhibitor eradication should be pursued in as many patients as possible. ITI is an effective tool, particularly in patients with severe hemophilia A and good risk profiles, and leads to a return to a normal factor VIII response in ∼60% of patients. However, for the group of patients who fail to respond to ITI or have hemophilia B, new and improved tools are needed.
authors.affiliation: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, and Department of Hematology and Medical Oncology, Emory University, Atlanta, GA.
authors.forename: Christine L
authors.initials: CL
authors.lastname: Kempton
authors.affiliation: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, and.
authors.forename: Shannon L
authors.initials: SL
authors.lastname: Meeks
mesh_terms: D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D015316:Genetic Therapy; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006470:Hemorrhage / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007108:Immune Tolerance; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D001779:Blood Coagulation Factors; D011994:Recombinant Proteins